ABSTRACT
It has been postulated that endothelial cell injury is the initiating event in the pathogenesis of systemic sclerosis, causing attraction, attachment, migration and infiltration of activated T cells and subsequent production of cytokines and growth factors. As a result of the action of these cytokines and growth factors, chemoattraction of fibroblasts into the vessel wall and trans-differentiation of resident fibroblasts and smooth Extensive recent studies have shown that statins display numerous effects independent of their well established lipid-lowering effect that may be of potential benefit in preventing vascular injury and ischemic vascular events. These effects may both prevent and improve vessel wall abnormalities, as well as, cause a local increase in the production and secretion of vasodilating molecules. Here, we review the current literature to provide support of a testable hypothesis that postulates that statins may have a modifying effect on the vasculopathy of systemic sclerosis.
INTRODUCTION
Vascular dysfunction and structural vessel wall abnormalities appear to be among the earliest alterations in systemic sclerosis. Indeed, it has been suggested that endothelial cell and vascular injury may be the crucial initiating event in the pathogenesis of this disorder (1, 2) . Endothelial dysfunction is one of three fundamental abnormalities characteristic of systemic sclerosis; the others being tissue fibrosis caused largely by increased collagen gene expression in dermal and visceral fibroblasts, and alterations in humoral and cell mediated immunity (3). The profound functional endothelial cell alterations in systemic sclerosis result in the progressive obliteration of the lumen of small arterioles and capillaries by newly formed fibrotic tissue causing a severe vasculopathy which most commonly involves the microvascular system. The most common clinical manifestation of this unique vasculopathy is the occurrence of Raynaud's phenomenon with narrowing and eventual occlusion of digital vessels.
However, visceral organs such as the kidneys, lungs, heart and skeletal muscle are also frequently involved (4).
Smooth muscle cells in the intimal layer of the vessel wall become activated likely owing to their transdifferentiation into myofibroblasts, migratory cells which characteristically display a marked increase in collagen production, causing an exaggerated deposition of collagen and other extracellular matrix macromolecules in the tissue. This fibroproliferative lesion coupled with the exaggerated vasoconstrictive vascular response typical of systemic sclerosis causes chronic hypoxia that leads to further endothelial injury and fibrosis. The severe vasomotor instability in these vessels is caused by 2c adrenergic hyperactivity, the local overproduction of vasoconstrictive substances such as endothelin, and the reduced production of local vasodilating agents such as NO. The narrowing of the vessel lumen and the endothelial dysfunction further propagate tissue ischemia by inducing platelet aggregation and local thrombosis (3, 4) .
Therapy for the vasculopathy of systemic sclerosis has included vasodilator agents such as calcium channel blockers, prostaglandins, phosphodiesterase inhibitors, endothelin receptor inhibitors, and agents causing increased NO production such as nitroglycerin (5), as well as, antiplatelet agents to prevent thrombotic vessel occlusion and platelet aggregation. Some of these agents such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, prostaglandins and endothelin receptor inhibitors have also been shown to cause some vascular remodeling and improvement of the intimal fibrotic lesion. In this regard, it is of substantial interest that recent studies have suggested that the statins may also interfere with the pathological changes in the vessel wall (6, 7) . It is well established that suppression of elevated total and low density lipoprotein cholesterol levels by statins promotes primary and secondary prevention of ischemic, atherosclerotic related events in patients with hypercholesterolemia (8) (9) (10) (11) (12) (13) . This effect was initially believed to be solely related to the cholesterol lowering effects of the statins, however, there is increasing evidence that these agents may exert profound endothelial and vascular protective effects beyond their lipid lowering action (14) (15) (16) . Indeed, experimental studies have shown that statins protect normocholesterolemic animals from the development of myocardial infarction (17) .
These later clinical and experimental observations have led to a wealth of research studies examining the pleiotropic effects of statins including modification of vascular pathology and have allowed the suggestion that these agents may have beneficial effects in other diseases accompanied by vasculopathy. In order to understand these pleiotropic effects, it is necessary to understand the metabolic pathways upon which these agents exert their cholesterol lowering effect. Statins inhibit the 3-hydroxy-3 methylglutanyl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the formation of mevalonate from HMG-CoA, the earliest step in the production of cholesterol (Figure1).
As can be seen in the diagram, mevalonate is also the precursor of isoprenoid groups which are required to modify post-translationally the Rho and Ras-superfamilies of proteins by attaching a hydrophilic prenyl group, either farnesyl or geranylgeranyl. The Rho and Ras proteins are small membrane-bound GTPases, which are active in the GTPbound state and inactive in the GDP-bound state. In their active state these proteins regulate important cellular functions including cell survival, proliferation and differentiation, as well as, cytoskeletal organization, by relaying extracellular ligandstimulated signals to cytoplasmic signaling cascades. It is the inhibition of prenylation of the Rho and Ras-related proteins by statins that is postulated to be responsible for some of the pleiotropic effects of this class of agents (18) (19) (20) (21) .
Making a Case for Statin Use in Systemic Sclerosis Vasculopathy
Statins as immune modulating agents. As described above, endothelial injury and the development of a vasculopathy have been postulated to be the initial pathogenic events in the development of systemic sclerosis. Endothelial injury which in some cases may be augmented by circulating antiendothelial antibodies (22) Endothelin-1 (ET-1) is a potent endothelium derived vasoconstrictor protein which appears to play an important role in the pathogenesis of systemic sclerosis ( Figure   2 ). The recent development of specific endothelin receptor blockers has shown that inhibition of ET-1 may be an effective therapy for the pulmonary arterial hypertension of systemic sclerosis. This approach also appears promising for the peripheral vasculopathy and the interstitial lung involvement of this disorder (45) . Statins have two effects on the ET-1 pathway. On the one hand, it has been shown that statins reduce pre-pro ET-1 mRNA expression, an effect which appears to be mediated by the inhibition of geranylgeranyl prenylation of RhoA (46, 47) . A second mechanism appears to be the decrease in the expression of endothelin receptors in vascular cells (48) .
Recent work also has shown that both cerivastatin and fluvastatin downregulate endothelial angiotensin II type I receptors, an effect also mediated by inhibition of prenylation of RhoA, thus potentially inhibiting the vasoconstrictive effect of angiotensin
II (49).
Statins as antifibrotic agents. Tissue fibrosis is the most prominent clinical manifestation of systemic sclerosis and is caused by the exaggerated accumulation of types I and III collagens and other connective tissue components in the extracellular matrix. Growth factors that play central roles in this process are transforming growth factor-1 (TGF-1) and connective tissue growth factor (CTGF) (3, 50) (Fig 2) . Statins have been shown to downregulate the expression of TGF-1 by renal mesangial cells in models of renal nephropathy in which fibrosis is mediated by TGF-1 and CTGF (51, 52) . Furthermore, statins cause potent reduction of CTGF mRNA levels in normal human and rodent mesangial cell lines, as well as, in human renal fibroblast cell lines, an effect also mediated by a decrease in geranylgeranyl prenylation of RhoA (53-55).
As part of the initiating events of any fibrotic disorder there is a proliferation or preferential selection of cells that have a profibrotic potential and/or transdifferentiation of cells with low extracellular matrix production capacity to cells with a much higher biosynthetic activity for molecules involved in the fibrotic process. The mesangial cells play this central role in diabetic nephropathy and other fibrotic nephropathies, whereas, in hepatic fibrosis and pulmonary fibrosis, the responsible cells are the stellate cells and the lung myofibroblasts, respectively. Statins have been shown in in vitro models of these fibrotic disorders to inhibit the proliferation of cells involved in the fibrotic process causing their increased apoptosis, as well as, causing a decrease in their production of extracellular matrix components. These results suggest that statins may also have a beneficial effect in various fibroproliferative disorders (56) (57) (58) .
Some studies have examined the effects of statins on cells from diseases associated with tissue fibrosis, however, only a few studied cells from patients with systemic sclerosis. In a recent in vitro study employing systemic sclerosis skin fibroblasts, we showed that GGTI-296, a specific inhibitor of geranylgeranyl transferase 1(GGT1) causes a potent inhibition (up to 80%) of the expression of genes encoding types I and III collagens (59) . This study suggested that inhibition of geranyl-geranyl prenylation by statins may also have similar effects to those of GGTI-296 on expression of collagen genes in systemic sclerosis fibroblasts. We therefore examined the in vitro effects of lovastatin and simvastatin on collagen production and type I collagen mRNA levels in cultured normal and systemic sclerosis dermal fibroblasts. We found that, indeed, both drugs were potent inhibitors of collagen production and caused a substantial reduction of collagen gene expression in these cells (60) . In agreement with these results, another study showed that atorvastatin inhibited in a dose dependent manner ICAM-1 expression on systemic sclerosis fibroblasts and reduced type I collagen production in both systemic sclerosis and normal fibroblasts (61) .
Other statin effects. Besides the immunomodulatory, vasodilating and antifibrotic effects discussed above, statins may also have antithrombotic and fibrinolytic effects by decreasing PAI-1 and increasing t-PA expression (62, 63) and may inhibit vascular smooth muscle cell proliferation (64) , decrease the release of reactive oxygen species (65), inhibit platelet function (66) and increase prostacyclin production from both endothelial and vascular smooth muscle cells (67) (Figure 2 ). These additional effects may also be of substantial value to improve the vasculopathy of systemic sclerosis. The remarkable modulation by statins of such diverse pathogenic cascades such as those involved in immune mediated inflammatory reactions, vascular tone regulation, production of increased levels of NO, and regulation of collagen gene expression have provided a cogent rationale for the use of statins in disorders other than those related to hypercholesterolemic and atherosclerotic disease. Indeed, some recent studies have examined the disease modifying effects of statins in disorders such as rheumatoid arthritis (34) and multiple sclerosis (35) . The vascular modifying effects discussed briefly here provide strong support to the testable hypothesis that statins may be of benefit in the treatment of the vasculopathy of systemic sclerosis and suggest that it may prove rewarding to investigate these effects in pre-clinical and clinical studies for systemic sclerosis, a disease in which the prominent endothelial cell dysfunction and vascular abnormalities have been suggested to play a crucial role in its pathogenesis and evolution.
Thus, we posit here that in systemic sclerosis, a disease for which few proven disease modifying agents are available, statins, which are readily available and have been demonstrated to be remarkably safe, are a promising alternative which deserves further studies. 
